HOME > TOP STORIES

TOP STORIES

REGULATORY Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached

December 19, 2013
ACADEMIA Chiba University Finds No Proof of Manipulation in Diovan Study

December 18, 2013
BUSINESS Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016

December 17, 2013
REGULATORY Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities

December 17, 2013
ACADEMIA Nagoya University Denies Diovan Clinical Data Manipulated

December 16, 2013
REGULATORY No Diovan, Livalo AGs for December Generic NHI Listing

December 13, 2013
BUSINESS AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps

December 13, 2013
REGULATORY PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks

December 12, 2013
BUSINESS Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease

December 12, 2013
ACADEMIA New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice

December 11, 2013
BUSINESS Takeda to Establish New CIO Post, Appoint Former Nestlé Exec

December 11, 2013
BUSINESS Drug Makers Invest in Developing AD Treatments

December 10, 2013
BUSINESS Ethical Drug Sales Up 2.5% in October: Crecon Report

December 10, 2013
REGULATORY FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition

December 9, 2013
BUSINESS “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End

December 9, 2013
BUSINESS Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use

December 6, 2013
BUSINESS Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated

December 5, 2013
REGULATORY Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely

December 5, 2013
BUSINESS Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca

December 4, 2013
BUSINESS Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later

December 3, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…